Shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) saw strong trading volume on Tuesday . 4,887,049 shares were traded during mid-day trading, an increase of 456% from the previous session’s volume of 879,553 shares.The stock last traded at $1.17 and had previously closed at $1.03.
Separately, HC Wainwright set a $12.00 price objective on DelMar Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, January 4th.
The firm has a market capitalization of $25.66, a price-to-earnings ratio of -1.64 and a beta of 1.22.
An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Susquehanna International Group LLP acquired a new position in DelMar Pharmaceuticals Inc (NASDAQ:DMPI) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 364,496 shares of the company’s stock, valued at approximately $306,000. Susquehanna International Group LLP owned approximately 1.69% of DelMar Pharmaceuticals at the end of the most recent reporting period. 16.94% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “DelMar Pharmaceuticals (DMPI) Sees Strong Trading Volume” was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3231093/delmar-pharmaceuticals-dmpi-sees-strong-trading-volume.html.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.